［1］Chen WQ，Zheng RT，He J，et al.An analysis of cancer incidence and mortality in China in 2012［J］.China Cancer，2016，25(01)：1-8.
［2］Kim HS，Pearson AT，Nr JE.Isolation and characterization of cancer stem cells from primary head and neck squamous cell carcinoma tumors［J］.Methods Mol Biol，2016，1395：241-249.
［3］Jiao X，Rizvanov AA，Cristofanilli M，et al.Breast cancer stem cell isolation［J］.Methods Mol Biol，2016，1406：121-135.
［4］Bussolati B，Bruno S，Grange C，et al.Isolation of renal progenitor cells from adult human kidney［J］.Am J Pathol，2005，166：545-555.
［5］Lapidary T，Sirrah C，Mormon J，et al.A cell initiating human acute myeloidleukemia after transplantation into SCID mice［J］.Nature，1994，367(6464)：645-648.
［6］Singh SK，Hawkins C，Clarke ID，et al.Identification of human brain tumour initiating cells［J］.Nature，2004，432(7015)：396-401.
［7］Wang X，Liu Y，Zhou K，et al.Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line［J］.Int J Clin Exp Pathol，2015，8(5)：5105-5112.
［8］Zhao X，Ran YL，Yu L，et al.In human hepatocellular carcinoma tissue isolation and culture of tumor stem cell-like cells［J］.Chin J Cancer Biother，2009，16(5)：436-441.
［9］Suetsugu A，Nagaki M，Aoki H，et al.Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.Biochem Biophys［J］.Res Commun，2006，351(4)：820-824.
［10］Ma S，Lee TK，Zheng BJ，et al.CD133+ HCC cancer stem cells confer resistance by preferential expression of the Akt/PKB survival pathway［J］.Oncogene，2008，27(12)：1749-1758.
［11］Chen Y，Yu D，Zhang H，et al.CD133+EpCAM+ phenotype possesses more characteristics of tumor initiating cells in hepatocellularcarcinoma Huh7 cells［J］.Int J Biol Sci，2012，8(7)：992-
1004.
［12］Song K，Kwon H，Han C，et al.Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells：regulation by MIR-122.［J］.Oncotarget，2015，6(38)：40822-40835.
［13］Yang ZF，Ho DW，Ng MN，et al.Significance of CD90+ cancer stem cells in human liver cancer［J］.Cancer Cell，2008，13(2)：153-166.
［14］Chen WC，Chang YS，Hsu HP，et al.Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer［J］.Oncotarget，2015，6(40)：42923-42937.
［15］Lee TK，Castilho A，Cheung VC，et al.CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation［J］.Cell Stem Cell，2011，9(1)
：50-63.
［16］Gao MQ，Choi YP，Kang S，et al.CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells［J］.Oncogene，2010，29(18)：2672-2680.
［17］Zhang J，Jiao J，Cermelli S，et al.miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apotheosis of CD24+ progenitor cells［J］.Cancer Res，2015，75(9)：
1859-1867.
［18］Chiba T，Kita K，Zheng YW，et al.Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties［J］.Hepatology，2006，44(1)：240-251.
［19］Niess H，Camaj P，Renner A，et al.Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistanceand metastasis［J］.Target Oncol，2015，
10(2)：215-227.
［20］Kim JB，Park SY，Kim HR，et al.JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancerdrugs［J］.Mol Med Rep，2015，11(1)：263-268.
［21］Zheng L，Jiang H，Zhang ZW，et al.Arsenic trioxide inhibits viability and induces apoptosis through reactivating the Wntinhibitor secreted frizzled related protein-1 in prostate cancer
cells［J］.Onco Targets Ther，2016，9：885-894.
［22］Cheng Y，Li Y，Ma C，et al.Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction［J］.Oncotarget，2016，7(11)：12683-12692.
［23］Chang S，Ma C，Pang H，et al.Arsenic trioxide suppresses cell growth and migration via inhibition of miR-27a in breast cancer cells［J］.Biochem Biophys Res Commun，2016，469(1)：55-61.
［24］Zhang KZ，Zhang QB，Zhang QB，et al.Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongsposthepatectomy survival by targeting GLI1expression in
a mouse model［J］.J Hematol Oncol，2014，7(28)：01-12.
［25］Li Y，Jiang F，Liu Q，et al.Inhibition of the cancer stem cells-like properties by arsenic trioxide，involved in the attenuation of endogenous transforming growth factor beta signal［J］
.Toxicol Sci，2015，143(1)：156-164.
［26］Yang X，Sun D，Tian Y，et al.Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl-2 expression［J］.Tumour Biol，2015，36(4)：2957-
2964.
［27］Wang H，Liu Y，Wang X，et al.Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma［J］.Cancer，2015，
121(17)：2917-2925.
［28］Chu TH，Chan HH，Kuo HM，et al.Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN［J］.Oncotarget，2014，5(6)：1475-1490.
［29］Guo Z，Jiang JH，Zhang J，et al.COX-2 promotes migration and invasion by the side population of cancer stem cell-like hepatocellularcarcinoma cells［J］.Medicine(Baltimore)，2015，94(44)
：e1806.
［30］Wang D，Fu L，Sun H，et al.Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice［J］.Gastroenterology，2015，149(7)：1884-1895.
［31］Galuppo R，Maynard E，Shah M，et al.Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPKand WNT/β-catenin pathways［J］.Anticancer Res，2014
，34(4)：1709-1713.
［32］Gedaly R，Galuppo R，Daily MF，et al.Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines withFH535［J］.PLoS One，2014，9(6)
：01-10.
［33］Sun LC，Zhao X，Ran YL，et al.Antibody -targeted therapy of hepatocarcinoma stem cell experiments［J］.Cancer Prevention Research，2011，39(6)：609-614.
［34］Meng F，Glaser SS，Francis H，et al.Functional analysis of microRNAs in human hepatocellular cancer stem cells［J］.J Cell Mol Med，2012，16(1)：160-173.
［35］You H，Ding W，Dang H，et al.Rountree CB.c-Met represents a potential therapeutic target for personalized treatment in Hepatocellular carcinoma［J］.Hepatology，2011，54(3)：879-889.